Publications by authors named "Elliott Winton"

Claim this Profile
P
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Elliott Winton

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Elliott F Winton

Blood· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
Daniel J DeAngelo, Deepti H Radia, Tracy I George, William A Robinson, Albert T Quiery, Elliott F Winton

Nat Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
Anand P Jillella, Martha L Arellano, Manila Gaddh, Amy A Langston, Leonard T Heffner, Elliott F Winton

JCO Oncol Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Alexander Coltoff, Ruben Mesa, Jason Gotlib, Jessica Shulman, Raajit K Rampal, Elliott F Winton

Clin Lymphoma Myeloma Leuk· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors.
Jee Hyun Kong, Elliott F Winton, Leonard T Heffner, Manila Gaddh, Brittany Hill

J Clin Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Abdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek, Josef T Prchal, Dmitry Berenzon, Elliott Winton

Blood· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
Hanna Jean Khoury, Amelia A Langston, Vamsi K Kota, Jennifer A Wilkinson, Iskra Pusic, Elliott Winton

Bone Marrow Transplant· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Claire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, Elliott F Winton

Lancet Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Ruben A Mesa, Jean-Jacques Kiladjian, John V Catalano, Timothy Devos, Miklos Egyed, Elliott F Winton

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
Vamsi K Kota, Jee Hyun Kong, Martha Arellano, Fuad El Rassi, Manila Gaddh, Elliott F Winton

Clin Lymphoma Myeloma Leuk· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Jee Hyun Kong, Elliott F Winton, Leonard T Heffner, Zhengjia Chen, Amelia A Langston

Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Ramon V Tiu, Elliott Winton

Lancet Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Elliott F Winton, Vamsi Kota

Future Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
John O Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M Foltz, Michael R Savona, Elliott Winton

Haematologica· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Vikas Gupta, John F DiPersio, Elliott F Winton

J Hematol Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Jonathon B Cohen, Silvana Bucur, Elliott F Winton, Rajni Sinha, Leonard T Heffner

Clin Lymphoma Myeloma Leuk· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib for the treatment of patients with polycythemia vera.
Jean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz, Srdan Verstovsek

Expert Rev Hematol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, Elliott F Winton

Haematologica· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?
Fuad El Rassi, John D Bergsagel, Martha Arellano, Manila Gaddh, Anand Jillella, Elliott F Winton

Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Kim-Hien T Dao, Magdolna B Solti, Julia E Maxson, Elliott F Winton, Richard D Press

Leuk Res Rep· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
Fuad El Rassi, Kevin C Ward, Christopher R Flowers, Leonard T Heffner, Edmund K Waller, Elliott F Winton

South Med J· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
Zahi Mitri, Momin T Siddiqui, Fuad El Rassi, Jeannine T Holden, Leonard T Heffner, Elliott Winton

Leuk Lymphoma· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, Elliott F Winton

Haematologica· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Moshe Talpaz, Ronald Paquette, Lawrence Afrin, Solomon I Hamburg, Josef T Prchal, Elliott F Winton

J Hematol Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis